Magnetic CAR T cell purification using an anti-G4S linker antibody.

CAR Isolation MACS Magnetic separation Purification

Journal

Journal of immunological methods
ISSN: 1872-7905
Titre abrégé: J Immunol Methods
Pays: Netherlands
ID NLM: 1305440

Informations de publication

Date de publication:
02 Apr 2024
Historique:
received: 09 01 2024
revised: 30 03 2024
accepted: 01 04 2024
medline: 5 4 2024
pubmed: 5 4 2024
entrez: 4 4 2024
Statut: aheadofprint

Résumé

Chimeric antigen receptor (CAR) redirected T cells are successfully employed in the combat against several hematological malignancies, however, are often compromised by low transduction rates making refinement of the CAR T cell products necessary. Here, we report a broadly applicable enrichment protocol relying on marking CAR T cells with an anti-glycine

Identifiants

DOI: 10.1016/j.jim.2024.113667 PMID: 38574803
pubmed: 38574803
pii: S0022-1759(24)00052-8
doi: 10.1016/j.jim.2024.113667
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113667

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Auteurs

Dennis Christoph Harrer (DC)

Department of Internal Medicine III - Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany; Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Regensburg, and Chair Genetic Immunotherapy, University Regensburg, Germany. Electronic address: dennis.harrer@ukr.de.

Sin-Syue Li (SS)

Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Regensburg, and Chair Genetic Immunotherapy, University Regensburg, Germany; Division of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Marcell Kaljanac (M)

Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Regensburg, and Chair Genetic Immunotherapy, University Regensburg, Germany.

Valerie Bezler (V)

Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Regensburg, and Chair Genetic Immunotherapy, University Regensburg, Germany.

Markus Barden (M)

Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Regensburg, and Chair Genetic Immunotherapy, University Regensburg, Germany.

Hong Pan (H)

Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Regensburg, and Chair Genetic Immunotherapy, University Regensburg, Germany.

Wolfgang Herr (W)

Department of Internal Medicine III - Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany.

Hinrich Abken (H)

Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Regensburg, and Chair Genetic Immunotherapy, University Regensburg, Germany.

Classifications MeSH